Clinical trials: Metastatic Nasopharyngeal Cancer
Nasopharyngeal Carcinoma
Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
The purpose of this study is to explore the efficacy and safety of a combination of Camrelizumab and Apatinib regimen in treating recurrent or metastatic nasopharyngeal carcinoma patients who have failed first-line platinum-based…
- Trial name
- NCT04547088
- Testing
- Camrelizumab, Apatinib
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer, Oral Complications of Radiation Therapy
Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer
RATIONALE: Iseganan hydrochloride may be effective in preventing or lessening oral mucositis in patients who are receiving radiation therapy for head and neck cancer.
- Conditions
- Head and Neck Cancer, Oral Complications of Radiation Therapy, Radiation Toxicity
- Trial name
- NCT00022373
- Testing
- iseganan HCl oral solution, management of therapy complications
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Cervical Cancer
EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma
RATIONALE: EF5 may detect the presence of oxygen in tumor cells and help plan effective cancer treatment. PURPOSE: Phase I trial to study the effectiveness of EF5 in detecting the presence of oxygen in tumor cells of patients who…
- Conditions
- Breast Cancer, Cervical Cancer, Head and Neck Cancer, Prostate Cancer
- Trial name
- NCT00004261
- Testing
- EF5, flow cytometry, fluorescent antibody technique
- Where
- Canada
- Sponsor
- University Health Network, Toronto
Nasopharyngeal Carcinoma
Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal Carcinoma
The investigators designed this study to evaluate the efficiency and the acute toxicities of recombinant human endostatin (endostar) combined with chemotherapy in the metastatic nasopharyngeal carcinoma (NPC).
- Trial name
- NCT01612286
- Testing
- endostatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.
This is a prospective, open-label phase III clinical trial evaluating the efficacy and safety of the GP（Gemcitabine combined with cisplatin） regimen in combination with Tislelizumab versus the TPC（cisplatin, nab-paclitaxel and…
- Trial name
- NCT06383780
- Testing
- GP combined with Tislelizumab, TPC combined with Tislelizumab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- XIANG YANQUN
Cancer
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499291
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation, gene expression analysis, laboratory biomarker analysis
- Sponsor
- Eastern Cooperative Oncology Group
Head and Neck Cancer
Gene Therapy in Treating Patients With Advanced Head and Neck Cancer
RATIONALE: Gene therapy may kill cancer cells by inhibiting a gene that promotes the development and growth of cancer. PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have advanced head…
- Trial name
- NCT00009841
- Testing
- EGFR antisense DNA, growth factor antagonist therapy, DC-cholesterol liposome
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Pittsburgh
Breast Cancer, Colorectal Cancer
Family Quality of Life Among Families With a Member Who is a Cancer Patient
RATIONALE: Developing a questionnaire that can be used to assess the quality of life among people who have a family member with cancer may help the study of cancer in the future.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00544336
- Testing
- questionnaire administration, survey administration, quality-of-life assessment
- Where
- 3 sites in United States
- Volunteers
- 366 people, healthy volunteers welcome
- Sponsor
- Vanderbilt-Ingram Cancer Center
Nasopharyngeal Carcinoma
Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
The purpose of this study is to explore the efficacy and safety of combination of Apatinib and Camrelizumab regimen in treating recurrent or metastatic nasopharyngeal carcinoma patients who were resistant to PD-1 antagonists.
- Trial name
- NCT04548271
- Testing
- Camrelizumab, Apatinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma
In this exploratory clinical trial, patients with newly diagnosed distant metastatic nasopharyngeal carcinoma were treated with gemcitabine+ cisplatin+PD-1 inhibitor regimen followed by whole-target radiotherapy (IMRT for local…
- Trial name
- NCT05431764
- Testing
- Camrelizumab, gemcitabin, cisplatin, Stereotactic Body Radiotherapy, Intensity modulated-radiotherapy
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy
The purpose of this single arm, phase Ⅱ clinical trial is to evaluate the efficacy and safety of Anlotinib Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma after failure of no less than second-line…
- Trial name
- NCT03906058
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma
In this multicenter, prospective, randomized, controlled, non-inferiority Phase III clinical trial, treatment-naïve patients with nasopharyngeal carcinoma (NPC) without metastasis will be enrolled for curative radiotherapy.
- Trial name
- OART (NCT06516133)
- Testing
- Intensity modulated radiation therapy (IMRT) with conventional planning target volume (PTV) margin and without online adaptive radiotherapy, Chemotherapy, Intensity modulated radiation therapy (IMRT) with smaller planning target volume (PTV) margin and online adaptive radiotherapy
- Where
- China
- Volunteers
- 494 people
- Sponsor
- Sun Yat-sen University
Effects of Chemotherapy, Stage IVC Nasopharyngeal Carcinoma
Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma
The investigators designed this study to evaluate the efficiency and the acute toxicities of recombinant human endostatin (endostar) combined with chemotherapy in the metastatic nasopharyngeal carcinoma (NPC).
- Trial name
- NCT01915134
- Testing
- Recombinant Human Endostatin plus gemcitabine and cisplatin, Gemcitabine and cisplatin
- Where
- China
- Volunteers
- 362 people
- Sponsor
- Zhejiang Cancer Hospital
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
This phase II trial is studying how well sunitinib works in treating patients with recurrent and/or metastatic head and neck cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx
- Trial name
- NCT00387335
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Nasopharyngeal Cancinoma (NPC)
EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma
Nearly all undifferentiated nasopharyngeal carcinoma (NPC) are associated with the Epstein-Barr Virus (EBV), which typically remains in a latent, non-immunogenic state within tumor cells.
- Trial name
- NCT07138989
- Testing
- Valganciclovir Hydrochloride Tablets, gemcitabine, cisplatin, and PD-1 antibody
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancinoma (NPC), Lymph Node Metastasis
A Deep Learning Model for Diagnosing Lymph Node Metastasis in Nasopharyngeal Carcinoma(NPC)
(I) AI Model for Diagnosing Lymph Node Metastasis We developed an AI model to help diagnose whether a single lymph node in nasopharyngeal cancer has spread. The model uses MRI images of the lymph node and the area around it.
- Trial name
- NPC (NCT06829147)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma
The standard of care for locally advanced nasopharyngeal carcinoma is radical chemoradiation(CRT).Recent advances in radiation techniques and supportive measures resulted in improvemnent of locoregional control and quality of…
- Trial name
- NCT04898374
- Testing
- Gemcitabin/cisplatin
- Where
- Kuwait
- Volunteers
- 120 people
- Sponsor
- Kuwait Cancer Control Center
Stage IV Nasopharyngeal Carcinoma
GC Regimen Chemotherapy Plus CIK Cells for Metastatic Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) is one of the most common malignant tumors in Southern China and South Asia. After radiotherapy, some patients with nasopharyngeal carcinoma still had distant metastasis.
- Trial name
- NCT01655628
- Testing
- GC chemotherapy plus CIK cells (Gemcitabine, Cisplatin, Autologous CIK cells), GC chemotherapy (Gemcitabine, Cisplatin)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Recurrent and Metastatic Nasopharyngeal Carcinoma
Nedaplatin Combined With Gemcitabine in the Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma : a Single Arm and Phase Ⅱ Clinical Trail
The purpose of this single arm,phase Ⅱ clinical trail is to determine the safety and efficacy of nedaplatin combined with gemcitabine in the treatment of recurrent and metastatic nasopharyngeal carcinoma
- Trial name
- NCT02789189
- Testing
- nedaplatin and gemcitabine
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University